Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study

Meiyu Wu, Jing Ma, Sini Li, Shuxia Qin, Chongqing Tan, Ouyang Xie, Andong Li, Aaron G. Lim () and Xiaomin Wan ()
Additional contact information
Meiyu Wu: The Second Xiangya Hospital, Central South University
Jing Ma: The Second Xiangya Hospital, Central South University
Sini Li: The Chinese University of Hong Kong
Shuxia Qin: The First Affiliated Hospital of Guangxi Medical University
Chongqing Tan: The Second Xiangya Hospital, Central South University
Ouyang Xie: The Second Xiangya Hospital, Central South University
Andong Li: The Second Xiangya Hospital, Central South University
Aaron G. Lim: Population Health Sciences, University of Bristol
Xiaomin Wan: The Second Xiangya Hospital, Central South University

PharmacoEconomics, 2024, vol. 42, issue 12, No 4, 1345-1357

Abstract: Abstract Background and Objective China has the highest number of hepatitis C virus (HCV) infections in the world. However, it is unclear what levels of screening and treatment are needed to achieve the WHO 2030 hepatitis C elimination targets. We aimed to evaluate the impact of scaling up interventions on the hepatitis C epidemic and determine how and at what cost these elimination targets could be achieved for the whole population in China. Methods We developed a compartmental model incorporating HCV transmission, disease progression, and care cascade for the whole population in China, calibrated with data on demographics, injecting drug use, HCV prevalence, and treatments. Five different scenarios were evaluated for effects and costs for 2022–2030. All costs were converted to 2021 US dollar (USD) and discounted at an annual rate of 5%. One-way sensitivity analyses were conducted to assess the robustness of the model. Results Under the status quo scenario, the incidence of hepatitis C is projected to increase from 60.39 (57.60–63.45) per 100,000 person-years in 2022 to 68.72 (65.3–73.97) per 100,000 person-years in 2030, and 2.52 million (1.94–3.07 million) infected patients are projected to die between 2022 and 2030, of which 0.76 (0.61–1.08) million will die due to hepatitis C. By increasing primary screening to 10%, conducting regular rescreening (annually for PWID and every 5 years for the general population) and treating 90% of patients diagnosed, the incidence would be reduced by 88.15% (86.61–89.45%) and hepatitis C-related mortality by 60.5% (52.62–65.54%) by 2030, compared with 2015 levels. This strategy would cost USD 52.78 (USD 43.93–58.53) billion. Conclusions Without changes in HCV prevention and control policy, the disease burden of HCV in China will increase dramatically. To achieve the hepatitis C elimination targets, China needs to sufficiently scale up screening and treatment.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-024-01424-5 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:42:y:2024:i:12:d:10.1007_s40273-024-01424-5

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-024-01424-5

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().